Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LC-SCRUM-Japan): Prospective analyses of clinicopathological and molecular characteristics in squamous cell lung cancer harboring FGFR alternation (LC-SCRUM-Japan-Sq)

Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LC-SCRUM-Japan): Prospective analyses of clinicopathological and molecular characteristics in squamous cell lung cancer harboring FGFR alternation (LC-SCRUM-Japan-Sq) - LC-SCRUM-Japan-Sq

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016607

Enrollment

600

Registered

2015-02-23

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed diagnosis of squamous cell lung cancer 2. Unresectable stage III-IV or postoperative recurrence patients unfitted for definitive hemoradiotherapy 3. Chemotherapy is planned regardless of pre-treatment history 4. Signed informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To clarify the clinicopathological and molecular feature in squamous cell lung cancer harboring FGFR gene alterations	—

Secondary

Measure	Time frame
To evaluate the frequencies and characteristics of any cancer-related gene alterations in squamous cell lung cancer using OCP(Cancer Panel)	—

Countries

Japan

Contacts

Public ContactKoichi Goto, Eri Sugiyama

National Cancer Center Hospital East Department of Thoracic Oncology

esugiyam@east.ncc.go.jp04-7133-1111

Outcome results